Marchés français ouverture 3 h 24 min

Intuitive Surgical, Inc. (ISRG)

NasdaqGS - NasdaqGS Cours en temps réel. Devise en USD
Ajouter à la liste dynamique
206,75+0,65 (+0,32 %)
À la clôture : 04:00PM EDT
206,70 -0,05 (-0,02 %)
Échanges après Bourse : 07:53PM EDT
Connectez-vous pour publier un message.

Tout commentaire contraire à la réglementation en vigueur (et notamment tout commentaire à caractère raciste, antisémite ou diffamatoire) pourra donner lieu à la suppression de votre compte Yahoo.

Le cas échéant, certains commentaires que vous postez pourront également donner lieu à des poursuites judiciaires à votre encontre.

  • T
    Timur
    Russia has about 30 da Vinci $ISRG robots and spent a little over 100 million dollars. The main complain is that it is too expensive to maintain. In many cases surgeons have to wait for new tools to come and do urgent operations by hand. China, Finland and some other countries certainly not buying da Vinci as it is too expensive for countries budgets. Titan Medical $TMD is another company that is trying to fight for the first place, so as TransEnterix. The reason I invested in $TRXC is because they actually analyzed the tooling cost and limitations of da Vinci system. $TRXC already spent over 220 million on robot development, by far this is the largest investment out of 50 other companies that are trying to compete. The spike in uptrend we see right now is not created by pumpers, this is natural growth and will increase quite fast. $TRXC will start with developing European market in 2021 to replace da Vinci and other systems there. I hope everyone already looked at the feedback from number of European hospitals. They will continue penetrating US market as well and will replace da Vinci eventually, but they still need to get a few more approvals to do so. I strongly believe in this company and hope that their cost effective system will save lots of lives.
  • r
    rp
    $TRXC conversation
    $TRXC is Robotics / AI growth sector going to $10 in a month and then higher. Look at $ISRG the competitor close to $800 with Market Cap of 92 Billion. $TRXC also is a better product as it provides feedback sensing to doctors that other competing products do not have. Institutions are already buying it as well. Holding for long-term. GLTA.
  • H
    Henry The Real
    $TRXC conversation
    This is impressive how this company renew itself, 2 years ago hospitals were not praising the product as they do now. They even compare with $ISRG product where $TRXC is now better. They've done major improvements and the strategy change seems promising.
  • R
    RJOHnWendyskid
    $TRXC conversation
    Reposting for Henry just to be on top of splain guy and Mia
    Meanwhile at $ISRG :
    - high cost system (lower for Senhance)
    - high cost maintenance (lower for Senhance : reusable instruments)
    - operating time (twice for a new user)
    - cost of training
    - no haptic feedback !! (Asensus provides such features)
    - market monopoly
    - general product with generic features that aims to operate both general and specific surgeries.

    So why would buy a product which is more expensive, which slows the operation and recovery and have been implied in many deaths...
  • T
    Timur
    $TRXC conversation
    $ISRG is down today, $TRXC has a chance to take their place. New CEO with his previous experience at Stryker can also bring value in adding new custom power tools. TRXC should invest a lot in their sales force and start presenting their solution in front of potential clients.
  • 👍RMO.BEST.EV.PLAY.245%UPSIDE✅💰
    🤑🤪🤑 From. The ISRG Board; Trading at $756 & Our only competition to TRXC a premium Robotics / AI growth sector going to $30 in a month and higher. Look at $ISRG the competitor close to $800 with Market Cap of 92 Billion. TRXC is a better product as it provides feedback sensing to doctors that other competing products do not have. Institutions are already buying it as well. Holding for long-term. Sell 1/3 at $30; 1/3 @ $75 1/3 @ $275 in one year
  • H
    Henry The Real
    $TRXC conversation
    The raise of Asensus will be fruitful in this current monopolized market.

    The main drawbacks of $ISRG are :
    - high cost system (lower for Senhance)
    - high cost maintenance (lower for Senhance : reusable instruments)
    - operating time (twice for a new user)
    - cost of training
    - no haptic feedback (Asensus provides such features)
    - market monopoly
    - general product with generic features that aims to operate both general and specific surgeries.
  • H
    Henry The Real
    $ASXC conversation
    Meanwhile at $ISRG :
    - high cost system (lower for Senhance)
    - high cost maintenance (lower for Senhance : reusable instruments)
    - operating time (twice for a new user)
    - cost of training
    - no haptic feedback !! (Asensus provides such features)
    - market monopoly
    - general product with generic features that aims to operate both general and specific surgeries.

    So why would buy a product which is more expensive, which slows the operation and recovery and have been implied in many deaths...
  • H
    Henry The Real
    $TRXC conversation
    Let’s check $ISRG history. Their first development were back in 80s ... 80s !!!!! And their first decent revenues in 2005... 2005!!
    Rome wasn’t build in a day.

    Source : https://en.m.wikipedia.org/wiki/Intuitive_Surgical
    Intuitive Surgical - Wikipedia
    en.m.wikipedia.org
  • K
    Kevin
    $TRXC conversation
    When a 'analyst' writes and article on how there's a case to become the next $ISRG you have to read it, and take it with a grain of salt. Those are awful big shoes to fill, but I think this has huge potential and a path to long running success. Dows anyone think Intuitive would buyout?
  • m
    mia
    $ASXC conversation
    ASXC
    better surgical technology than
    $ISRG
    . "In a recent study, Dr. Steven McCarus, Chief of Gynecological Surgery at AdventHealth Winter Park and AdventHealth Celebration, assessed 15 patients undergoing laparoscopic gynecological surgery with the SenhanceⓇ Surgical System. Minimal pain medication was used and patient satisfaction with the surgery was 98%; satisfaction with scarring was 100%.
    Dr. McCarus also found that the Senhance System provided more surgeon control over both camera and tools compared to previously used robotic systems and traditional laparoscopic surgery."
  • R
    Rock
    It’s a triple digit jewel. It’s peer $ISRG was $3 in 2005. I am going to keep adding for long play
  • r
    richie
    $ISRG conversation
    IS $TRXC the next $ISRG?
    Time will tell, but this is one lotto ticket I'm holding onto as they have little debt, cash on hand, & product being sold.
  • 👍RMO.BEST.EV.PLAY.245%UPSIDE✅💰
    🤑✅🤑 IS TransEnterix a good buy? one might ask; Well, THE ONLY COMPETITION is $ISRG trading north of $750; TRXC is trading north of $5 with a $75 price target! So DO THE MATH! Oh; and LOAD UP THE TRUCK!
  • H
    Henry The Real
    $ASXC conversation
    Compare this stock as a startup without the drawbacks like :
    - huge debt (because there is none)
    - lack of cash (because they are full of cash 125M)
    - unfinished product (because it exists and continuously improved, yet it have features competitors like the giant $ISRG does not have - haptic feedback)

    Also, the paid bashers should stop defaming other users.
  • H
    Henry The Real
    $TRXC conversation
    Here some facts :
    $ISRG
    https://en.wikipedia.org/wiki/Intuitive_Surgical
    https://en.wikipedia.org/wiki/Da_Vinci_Surgical_System
    Adverse Events in Robotic Surgery: A Retrospective Study of 14 Years of FDA Data
    https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4838256/
    da Vinci Surgical Robots Have Been Linked to At Least 144 Deaths
    https://www.mcgowanhood.com/2018/09/13/da-vinci-surgical-robots-have-been-linked-to-at-least-144-deaths/#:~:text=Instead%2C%20it's%20led%20to%20a,study%20published%20in%20PLoS%20One.
    Conversion from robotic surgery to laparotomy: A case-control study evaluating risk factors for conversion
    https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4125462/

    $TRXC
    Single-port cholecystectomy with the TransEnterix SPIDER: Simple and safe
    https://www.researchgate.net/publication/26817971_Single-port_cholecystectomy_with_the_TransEnterix_SPIDER_Simple_and_safe
    First Clinical Use of 5 mm Articulating Instruments with the Senhance® Robotic System
    https://pubmed.ncbi.nlm.nih.gov/32926398/

    $ISRG vs $TRXC
    https://finpedia.co/bin/TransEnterix/#H2020PublicOfferings
    https://finpedia.co/bin/download/TransEnterix/WebHome/TransEnterix2.png?rev=1.1

    Investors $TRXC from Tipranks
    https://www.tipranks.com/stocks/trxc/stock-investors
    The research that eventually led to the development of the da Vinci Surgical System was performed in the late 1980s at a non-profit research institute SRI International.[5] In 1990, SRI received funding from the National Institutes of Health. SRI d
    The research that eventually led to the development of the da Vinci Surgical System was performed in the late 1980s at a non-profit research institute SRI International.[5] In 1990, SRI received funding from the National Institutes of Health. SRI d
    en.wikipedia.org
  • 👍RMO.BEST.EV.PLAY.245%UPSIDE✅💰
    🤑🚨👍 EASIEST QUADRUPLE PLAY I’ve ever seen. Long term 10 X Compare TRXC with $ISRG. Miles ahead in product advancement. Just needing the sales catalyst. Once that hits 🚀🚀🚀🚀
  • H
    Henry The Real
    $TRXC conversation
    Watch SEC... $ISRG CFO selling shares.
  • 👍RMO.BEST.EV.PLAY.245%UPSIDE✅💰
    🤪OVER 1 HR AGO TOLD YOU NEWS LEAKD.
    ⚠️🆘❤️ GRANTED US PATENT ❤️🆘⚠️ Endoscopic Control system $ISRG would die to have. $100 PRICE TARGET 🎯
  • S
    StockStuffer
    $ASYS conversation
    The robotic surgery market includes
    $MDT market cap 158B
    $ISRG market cap 94B
    $SYK market cap 91B
    $ZBH market cap 34B
    $EDAP
    A lesser known play that uses high frequency ultrasound to target cancer without the incision is EDAP if you want to broaden the portfolio. The robotics guides the waves and essentially burns the cancer cells killing them and the body takes care of the rest.